202 related articles for article (PubMed ID: 24725174)
1. Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides.
Daggett RN; Kurata M; Abe S; Onishi I; Miura K; Sawada Y; Tanizawa T; Kitagawa M
Br J Dermatol; 2014 Oct; 171(4):722-31. PubMed ID: 24725174
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4.
Aronovich A; Moyal L; Gorovitz B; Amitay-Laish I; Naveh HP; Forer Y; Maron L; Knaneh J; Ad-El D; Yaacobi D; Barel E; Erez N; Hodak E
J Invest Dermatol; 2021 Mar; 141(3):619-627.e2. PubMed ID: 32795528
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.
Vermeer MH; Geelen FA; Kummer JA; Meijer CJ; Willemze R
Am J Pathol; 1999 Apr; 154(4):1203-10. PubMed ID: 10233858
[TBL] [Abstract][Full Text] [Related]
4. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
6. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA.
Asadullah K; Döcke WD; Haeussler A; Sterry W; Volk HD
J Invest Dermatol; 1996 Dec; 107(6):833-7. PubMed ID: 8941670
[TBL] [Abstract][Full Text] [Related]
7. The number of regular T cells and immature dendritic cells involved in mycosis fungoides is linked to the tumor stage.
Zhang QA; Chen ZQ; Chen MH; Xu ZD
Eur Rev Med Pharmacol Sci; 2014; 18(4):553-8. PubMed ID: 24610622
[TBL] [Abstract][Full Text] [Related]
8. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
9. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
[TBL] [Abstract][Full Text] [Related]
10. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
[TBL] [Abstract][Full Text] [Related]
11. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.
Kakinuma T; Sugaya M; Nakamura K; Kaneko F; Wakugawa M; Matsushima K; Tamaki K
J Am Acad Dermatol; 2003 Jan; 48(1):23-30. PubMed ID: 12522366
[TBL] [Abstract][Full Text] [Related]
12. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
13. miR-155 is involved in tumor progression of mycosis fungoides.
Moyal L; Barzilai A; Gorovitz B; Hirshberg A; Amariglio N; Jacob-Hirsch J; Maron L; Feinmesser M; Hodak E
Exp Dermatol; 2013 Jun; 22(6):431-3. PubMed ID: 23711069
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining for CD45R isoforms in paraffin sections to diagnose mycosis fungoides-type cutaneous T-cell lymphoma.
Ismail SA; Han R; Sanborn SL; Stevens SR; Cooper KD; Wood GS; Gilliam AC
J Am Acad Dermatol; 2007 Apr; 56(4):635-42. PubMed ID: 17367612
[TBL] [Abstract][Full Text] [Related]
15. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
Chen GS; Yu HS; Lan CC; Chow KC; Lin TY; Kok LF; Lu MP; Liu CH; Wu MT
Br J Dermatol; 2006 May; 154(5):910-8. PubMed ID: 16634895
[TBL] [Abstract][Full Text] [Related]
16. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides.
Maj J; Jankowska-Konsur AM; Hałoń A; Woźniak Z; Plomer-Niezgoda E; Reich A
Postepy Dermatol Alergol; 2015 Dec; 32(6):437-42. PubMed ID: 26755907
[TBL] [Abstract][Full Text] [Related]
17. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides.
Furudate S; Fujimura T; Kakizaki A; Kambayashi Y; Asano M; Watabe A; Aiba S
Exp Dermatol; 2016 Feb; 25(2):107-12. PubMed ID: 26441016
[TBL] [Abstract][Full Text] [Related]
18. CXCR4: A Potential Marker for Inflammatory Activity in Abdominal Aortic Aneurysm Wall.
Tanios F; Pelisek J; Lutz B; Reutersberg B; Matevossian E; Schwamborn K; Hösel V; Eckstein HH; Reeps C
Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):745-53. PubMed ID: 26346005
[TBL] [Abstract][Full Text] [Related]
19. Expression of human beta-defensins in patients with mycosis fungoides.
Gambichler T; Skrygan M; Appelhans C; Tomi NS; Reinacher-Schick A; Altmeyer P; Kreuter A
Arch Dermatol Res; 2007 Jul; 299(4):221-4. PubMed ID: 17415576
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis.
Gu X; Wang Y; Zhang G; Li W; Tu P
J Dermatol; 2013 Aug; 40(8):596-605. PubMed ID: 23682716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
